SCYXライブシグナル | Getagraph.comで利益を最大化

Live Chart Being Loaded With Signals

Commentary (30 4月 2024 @ 01:46):

Stats
本日の出来高	162 737
平均出来高	201 998
時価総額	65.69M
EPS	$-0.390 ( 2024-03-29 )
次の収益日	( $-0.180 ) 2024-05-09
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	1.250
ATR14	$0.0100 (0.57%)

Insider Trading

Date	Person	Action	Amount	type
2024-02-16	Sukenick Scott	Sell	15 179	Common Stock
2024-01-26	Angulo Gonzalez David	Buy	290 590	Common Stock
2024-01-26	Angulo Gonzalez David	Buy	431 030	Employee Stock Option (Right to Buy)
2024-01-26	Macleod Ivor	Buy	215 515	Employee Stock Option (Right to Buy)
2024-01-26	Macleod Ivor	Buy	143 675	Common Stock

INSIDER POWER
98.25
Last 93 transactions
Buy: 4 299 100 \| Sell: 614 179

ボリューム相関

長: 0.06 (neutral)

短: -0.01 (neutral)

Signal:(52.969) Neutral

SCYNEXIS Inc 相関

10 最も正の相関
XELA	0.888
ZSAN	0.887
QLGN	0.874
SWVL	0.874
KTTA	0.866
SMIT	0.858
LGMK	0.858
XFOR	0.855
QAT	0.854
NVAX	0.853

10 最も負の相関
CROX	-0.88
AVAC	-0.874
FNVT	-0.872
GDNR	-0.871
BTWN	-0.87
XENT	-0.869
MLVF	-0.866
ADAL	-0.864
CNGL	-0.863
HWCC	-0.862

知っていましたか？

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関（1つの変数が増加すると、もう一方は減少する）、1は完全な正の相関（1つの変数が増加すると、もう一方も増加する）、0は相関がないことを示します（変数間に関係がない）。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

SCYNEXIS Inc 相関 - 通貨/商品

-0.15
( neutral )

-0.56
( weak negative )

0.00
( neutral )

-0.37
( neutral )

0.06
( neutral )

-0.10
( neutral )

SCYNEXIS Inc 財務諸表

Annual	2023
収益:	$140.14M
総利益:	$123.71M (88.27 %)
EPS:	$1.400

FY	2023
収益:	$140.14M
総利益:	$123.71M (88.27 %)
EPS:	$1.400

FY	2022
収益:	$5.09M
総利益:	$4.46M (87.66 %)
EPS:	$-1.470

FY	2021
収益:	$13.16M
総利益:	$12.85M (97.63 %)
EPS:	$-1.250

Financial Reports:

No articles found.

SCYNEXIS Inc

SCYNEXIS, Inc., a biotechnology company, develops products for the treatment fungal infections in the United States. It offers BREXAFEMME (ibrexafungerp tablets) for the treatment of vulvovaginal candidiasis (VVC). The company is developing its lead product candidate, Ibrexafungerp, as a novel oral and intravenous drug for the treatment of various fungal infections, including recurrent VVC, invasive aspergillosis, invasive candidiasis, and refractory invasive fungal infections; and ibrexafungerp that has completed Phase 3 CANDLE study for the prevention of recurrent (VVC). It has research collaborations with Merck Sharp & Dohme Corp., Hansoh (Shanghai) Health Technology Co., Ltd., Jiangsu Hansoh Pharmaceutical Group Company Limited, and R-Pharm, CJSC to develop and commercialize rights for ibrexafungerp. The company was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. SCYNEXIS, Inc. was incorporated in 1999 and is headquartered in Jersey City, New Jersey.